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Results of the Protégé EverFlex 200-mm-long
nitinol stent (ev3) in TASC C and D
femoropopliteal lesions
Marc Bosiers, MD,a Koen Deloose, MD,a Joren Callaert, MD,a Nathalie Moreels, MD,a
Koen Keirse, MD,b Jürgen Verbist, MD,b and Patrick Peeters MD,b Dendermonde and Bonheiden, Belgium
Objectives: This study investigated the results with primary stenting using the Protégé EverFlex 200-mm-long self-
expanding nitinol stent (ev3 Endovascular Inc, Plymouth, Minn) in femoropopliteal TransAtlantic Inter-Society
Consensus (TASC) C and D lesions of at least 150 mm in length.
Methods: Between March 2008 and June 2009, 100 patients (66 men) presenting with 100 symptomatic TASC C and D
femoropopliteal lesions were treated with at least one 200-mm-long Protégé EverFlex stent. The intention of this study
was to treat all lesions with as few stents as possible. The primary study end point was primary patency at 12 months,
defined as the absence of hemodynamically significant stenosis on duplex ultrasound imaging (systolic velocity ratio<2.4)
at the target lesion and without target lesion revascularization (TLR)<12 months. Stent fracture occurrence was assessed
at the 12-month follow-up by conventional x-ray imaging.
Results: Average patient age was 70 years. Preoperative symptom assessment reported 71 patients (71%) had claudication
vs 29 (29%) with critical limb ischemia. Average lesion length was 242 mm (range, 160-450 mm), and 27 patients (27%)
presented with popliteal involvement. A total of 158 Protégé EverFlex stents were used to treat 100 lesions. Kaplan-Meier
estimation reported a 12-month freedom from target lesion revascularization of 68.2% and a primary patency rate of
64.8%. Stent fractures occurred in six patients (6.0%) when x-ray images taken immediately after the procedure were
compared with those taken after 1 year.
Conclusions: The results of our Durability-200 study show an acceptable primary patency rate after 1 year was obtained
in this patient cohort with TASC C and D femoropopliteal lesions. ( J Vasc Surg 2011;54:1042-50.)
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nSurgical bypass for severe lower extremity atherosclero-
sis is an effective treatment in patients presenting with
claudication or critical limb ischemia. To date, autologous
vein bypass is considered the gold standard.1,2 In patients
without a suitable long saphenous vein, the implantation of
prosthetic grafts, either expanded polytetrafluoroethylene
(ePTFE) or Dacron, is also associated with favorable long-
term results.3-7
Open surgery is not always possible, however, due to
prohibitive comorbidities, unsuitable conduit, or lack of an
adequate distal target for revascularization. Moreover, the
recent technologic advances in endovascular therapy have
extended the applicability of minimally invasive treatment
for challenging superficial femoral artery lesions that were
previously deemed unsuitable for endovascular repair. Cur-
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1042ent infrainguinal endovascular options include balloon
ngioplasty, subintimal angioplasty, angioplasty with selec-
ive stenting, and primary stenting. Several trials have been
ublished; however, the debate continues about which
ndovascular treatment is preferable.
The introduction of long and flexible stent designs has
pened new perspectives for long-lasting endovascular
reatment of challenging femoropopliteal lesions. The
urability-200 study is the first trial investigating the re-
ults with primary stenting using Protégé EverFlex 200-
m-long self-expanding nitinol stents (ev3 Endovascular
nc, Plymouth, Minn) in femoropopliteal TransAtlantic
nter-Society Consensus (TASC) C and D lesions at least
50 mm in length.
ATERIALS AND METHODS
The Durability-200 was a prospective, nonrandom-
zed, dual-center, controlled trial performed at the Depart-
ent Vascular Surgery at the Algemeen Ziekenhuis Sint-
lasius (Dendermonde, Belgium) and at the Department
f CardioVascular and Thoracic Surgery at Imelda Hospital
Bonheiden, Belgium). It was registered with http://
linicalTrials.gov Identifier NCT00637741.
The investigational device tested in the Durability-200
as the 200-mm-long self-expanding Protégé EverFlex
itinol stent. The Protégé EverFlex nitinol stent system is
onformité Européene-approved and indicated for use in
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Volume 54, Number 4 Bosiers et al 1043patients with atherosclerotic disease of peripheral arteries.
Patients eligible for Durability-200 had to present with
TASC C or D femoropopliteal lesions, according to the
TASC II (2007) recommendations.8 The target lesion had
to be located in the native femoropopliteal artery, with its
most distal point maximally 3 cm proximal to the knee
joint. The target vessel diameter had to be minimally 4 mm
and maximally 6.5 mm, by visual estimation.
Every patient enrolled in this study had to receive at
least one 200-mm-long Protégé EverFlex stent. The study
intention was to treat all lesions with as few stents as
possible. Additional stent placement was allowed whenever
the investigators deemed this was necessary to obtain com-
plete target lesion coverage. Stent lengths200 mm could
be used as second and third stents, provided that only
Protégé Everflex stents were used and that the entire lesion
length was covered by as few stents as possible.
The initial study sample size was 60 patients, as set
by protocol v1.00 dd 080211, which was submitted to the
Local Ethics Committee of the Algemeen Ziekenhuis
Sint-Blasius and the Central Ethics Committee of Imelda
Hospital. After submission of protocol amendment v2.00
dd 081105 to the Ethics Committees, this number was
raised to 100 patients.
End points. The primary end point of the study was
primary patency at 12 months, defined as the absence of
hemodynamically significant stenosis on duplex ultrasound
imaging at the target lesion and without target lesion
revascularization (TLR) 12 months. Peak systolic veloci-
ties (PSV) were recorded 1 cm proximal to and 1 cm distal
to the stented area, together with the highest PSV measure-
ment inside the stented area. The grading of a stenosis was
determined by the ratio with the normal PSV waveform as
the denominator and the PSV in the stented portion as the
numerator, which was defined as proximal peak velocity
ratio. A peak systolic velocity ratio of 2.4 was considered
hemodynamically significant.
Secondary end points of Durability-200 were:
1. technical success, defined as the ability to cross and
dilate the lesion to achieve residual angiographic steno-
sis of 30% and residual stenosis of 50% by duplex
imaging;
2. primary patency rate at 6- and 12-months of follow-up;
3. clinical success at follow-up, defined as an improve-
ment of Rutherford classification at 6- and 12-month
follow-up of one class or more compared with the
preprocedure Rutherford classification;
4. stent fracture rate at the 12-month follow-up by x-ray
imaging, categorized as mild (fracture of 1 strut), mod-
erate (fracture of 1 strut but without complete sepa-
ration), or severe (complete separation); and
5. serious adverse events, defined as any clinical event that
was fatal, life-threatening, or judged to be severe by the
investigator; resulted in persistent or significant disabil-
ity; necessitated surgical or percutaneous intervention;
or required prolonged hospitalization. bPatients were eligible for enrollment in Durability-200
hen they complied with all general inclusion criteria and
ll angiographic inclusion criteria, as specified in Table I,
nd when none of the exclusion criteria were met, as
pecified in Table II. After verification of the inclusion and
xclusion criteria, written informed consent for the collec-
ion of personal medical data was obtained for each patient
efore enrollment in the trial.
Procedure and hospitalization. All eligible patients
nderwent a baseline clinical examination to collect clinical
ata before the procedure. This consisted of medical his-
ory, medication record, physical examination, clinical cat-
gory of critical limb ischemia according to the Rutherford
lassification9 by means of a Walking Impairment Ques-
ionnaire (WIQ), and ankle-brachial index (ABI) at rest.
he baseline vascular risk factors collected were history of
icotine abuse, presence of arterial hypertension, diabetes
ellitus, renal insufficiency (serum creatinine1.2 mg/dL
n men or 0.9 mg/dL in women), hypercholesterolemia
total cholesterol 190 mg/dL), and obesity, defined as a
ody mass index (BMI) 25 kg/m2. To be included,
atients needed to have an abnormal ABI at rest. Evidence
f disease was assessed by color-flow Doppler ultrasound
CFDU) imaging and duplex scanning, when performed.
inal assessment of the lesion severity had to be confirmed
y procedural angiography.
Vascular access was achieved, and all inflow-limiting
esions were treated according to the investigator’s stan-
ard clinical practice. Lesion crossing with an approved
onventional guidewire was obtained up to the distal vessel
able I. Inclusion criteria
eneral inclusion criteria
De novo, restenotic, or reoccluded lesion located in the femo-
ropopliteal arteries suitable for stenting
Patient presents a score of 2 to 5 after Rutherford classification
Patient is willing to comply with specified follow-up evalua-
tions at the specified times
Patient is aged 18 years
Patient (or his or her legal representative) understands the
nature of the procedure and provides written informed con-
sent before enrollment in the study
Before enrollment, the guidewire has crossed target lesion
Patient is eligible for treatment with the self-expanding nitinol
EverFlex (ev3) stent
ngiographic inclusion criteria
The target lesion is located within the native femoropopliteal
artery until maximally 3 cm proximal of the knee joint
The target lesion has angiographic evidence of stenosis or re-
stenosis 50% or occlusion, which can be passed with stan-
dard guidewire manipulation
The target lesion, visually estimated, has a minimal length of
15 cm and can be categorized as either a type C or D lesions
according the TASC II guidelines
Target vessel diameter visually estimated is 4 mm and 6.5
mm
There is angiographic evidence of at least one vessel runoff to
the foot
ASC, TransAtlantic Inter-Society Consensus.eyond the target lesion. Whenever free movement of the
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October 20111044 Bosiers et alwire tip within the distal vessel lumen was not observed, the
guidewire was withdrawn and redirected. To ensure in-
traluminal position of the guidewire, a low-profile infusion
catheter could be advanced over the guidewire distal to the
target lesion. Distal runoff was ensured after withdrawal of
the guidewire and contrast media injection through the
infusion catheter. After successful lesion passage, diagnostic
angiography of the lesion area and distal runoff was per-
formed, and upon confirmation of the angiographic inclu-
sion criteria, the patient was enrolled in the study.
Stent implantation was performed according to the
standard procedures stipulated in the instructions for use
available for the Protégé EverFlex stent. Each patient re-
ceived at least one 200-mm-long stent, and the investigator
used as few stents as possible to obtain complete lesion
coverage. Predilation and postdilation were performed ac-
cording to the physician’s discretion. Finalization of the
endovascular intervention was performed by acquiring he-
mostasis through manual compression or the application of
a closure device.
Immediately after the procedure, conventional x-ray
imaging was performed in two planes with at least a 45°
difference in inclination between both angles, with maxi-
mal opacification and zoom. This served as a reference to be
used for comparison with the images obtained at the 12-
month follow-up, which had to be captured in the same
two planes, to assess stent fracture occurrence.
The study protocol did not mandate any scheme for
concomitant medication during the hospital stay and
Table II. Exclusion criteria
● Presence of another stent in the target vessel that was placed
during a previous procedure
● Presence of aortic thrombosis or significant common femoral
ipsilateral stenosis
● Previous bypass surgery in the same limb
● Patients for whom antiplatelet therapy, anticoagulants, or
thrombolytic drugs are contraindicated
● Patients who exhibit persistent acute intraluminal thrombus of
the proposed lesion site
● Perforation at the angioplasty site evidenced by extravasation
of contrast medium
● Patients with known hypersensitivity to nickel-titanium
● Patients with uncorrected bleeding disorders
● Aneurysm located at the level of the superficial femoral artery
● Female patient with child-bearing potential not taking ade-
quate contraceptives or currently breastfeeding
● Life expectancy of 12 months
● Ipsilateral iliac treatment before the target lesion procedure
with a residual stenosis 30% or ipsilateral iliac treatment con-
ducted after the target lesion procedure
● Use of thrombectomy, arthrectomy, or laser devices during
the procedure
● Any planned surgical intervention or procedure within 30 days
of the study procedure
● Any patient considered to be hemodynamically unstable at
onset of the procedure
● Patient is currently participating in another investigational
drug or device study that has not completed the entire fol-
low-up periodfollow-up. However, it was recommended that patients be (iven clopidogrel (75 mg/d) for 1 month, assurance of
lopidogrel saturation before the procedure, and lifelong
dministration of aspirin (75 to 300 mg/d). In case of
ossible thrombosis, thrombolytic or antiplatelet therapy
ould be used in conjunction with the intervention, accord-
ng to institutional protocols.
Tests required immediately after the procedure were
ngiography and high-intensity cine-run. Tests before dis-
harge included CFDU and duplex scanning, Rutherford
ategorization, and ABI.
Follow-up. Clinical follow-up data were collected at
, 6, and 12 months. Other follow-up data collected con-
isted of data from unplanned or interim follow-up visits
nd reports of patient deaths. Regular follow-up visits
nsured monitoring the patient’s condition and the stent or
rocedure, or both. Patients were to adhere to a follow-up
isit time restriction of7 days for the 1-month follow-up
nd 30 days for the 6- and 12-month follow-up visits.
After 1 month, medication registration, physical exam-
nation, ABI measurements, and clinical categorization of
ritical limb ischemia according to the Rutherford catego-
ization was required. After 6 months, all 1-month investi-
ations were repeated and supplemented with a CFDU
maging (duplex scanning) at the treated vessel. After 1
ear, all 6-month investigations were performed, together
ith a biplanar x-ray examination, which was compared
ith the x-ray images taken immediately postoperatively.
o be able to adequately interpret the x-ray images, sepa-
ate images were taken for every stent implanted in two
lanes with maximal opacification and zoom.
Data collection and statistical analysis. Double-data
ntry was performed in an electronic database to generate
escriptive data summaries. Categoric variables were ren-
ered by frequency distributions and cross tabulations.
ontinuous variables were reported by calculation of mean
range) and median (standard deviation). For all variables, a
5% confidence interval for the relevant parameters of the
nderlying distribution were used. Kaplan-Meier estima-
ions were calculated for life-tables of all time-dependent
vents, for the period starting on the date of the procedure
p to and including the 12-month follow-up visit, with the
se of MedCalc software (MedCalc Software, Mariakerke,
elgium). Stratification to preprocedural risk factors, Ruth-
rford classification, and lesion criteria were performed and
ompared by the log-rank test, reporting differences in
utcomes. Associated values of P  .05 were considered
ignificant. All periprocedural and postprocedural compli-
ations (24 hours) were evaluated and documented.
ESULTS
Between March 2008 and June 2009, 131 patients
ith symptomatic femoropopliteal arterial obstructive le-
ions of at least 150 mm met the inclusion criteria. Of them,
7 refused to sign informed consent, and the wire crossing
as not successful in four patients. Technical success was
chieved in the remaining 100 patients (66 men), and no
atients had a residual stenosis after treatment of 30%
angiographic control) or50% (duplex control). Average
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Volume 54, Number 4 Bosiers et al 1045age was 70 years (range, 46-87 years). Baseline vascular risk
factors reported a history of nicotine abuse in 56 patients
(56%), of which 37 (66%) were still current smokers; 61
(61%) had arterial hypertension, with 50 (82%) controlled
by medical therapy; diabetes mellitus was present in 27
(27%), of which 11 (37.9%) were insulin-dependent; and
renal insufficiency was present in 21 (21%), hypercholester-
olemia in 41 (41%), and obesity in 23 (23%).
The preoperative symptom assessment reported 40 pa-
tients (40%) with a walking distance of 100 to 250 meters
(Rutherford category 2); 31 (31%) had a limited walking
distance 100 meters (Rutherford category 3); 14 (14%)
had rest pain (Rutherford category 4), and 15 (15%) had
nonhealing arterial ulcers (Rutherford 5). This brought the
total number of claudicant patients to 71 (71%) vs 29
critical limb ischemia patients (29%).
Looking at the lesion allocation and configuration, 50
right limbs (50%) were treated. Average lesion length was
242 mm (range, 160-450 mm), and 49 lesions (49%) were
between 150 and 200 mm in length. Popliteal involvement
was present in 27 patients (27%). Calcified lesions were
reported in 79 (79%). There were 75 patients (75%) with
three patent outflow vessels, 16 (16%) with two outflow
arteries, and nine (9%) with only one outflow vessel.
Technical success was achieved in all 100 patients
(100%), and 158 Protégé EverFlex stents were used to treat
the 100 lesions. Placement of one stent was reported in 49
patients (49%), which corresponded with the number of
lesions between 150 and 200 mm in length. Dual stents
were used in 44 patients (44%), and three stents were
deployed in seven (7%). When multiple stents were used,
the observed overlap zone was between 10 and 30 mm in
length.
Five patients experienced a complication before being
discharged from the hospital. One patient had postproce-
dural blood loss and went into a hemorrhagic shock with
ischemia of the left leg caused by an in-stent occlusion in
the study lesion. He had a reintervention by means of
endovascular thrombectomy, followed by dilation and
stent placement at the occluded segment. This patient was
considered to have a loss of primary patency. In two pa-
tients, a stenosis of the common femoral artery occurred at
the puncture site on the contralateral limb before discharge
from the hospital. Immediate dilation of this stenotic seg-
ment was performed. Two patients with distal embolization
were successfully treated by endovascular aspiration in the
below-knee arteries.
The 30-day mortality rate was 1%, with one patient who
died on the day after the procedure of septic shock induced
by methicillinresistant Staphyloncus aureus. Other 30-day
complications occurred in four other patients. Blood loss in
one patient after the procedure resulted in hemorrhagic
shock and an in-stent reocclusion causing ischemia of the
left leg. Endovascular thrombectomy was successfully per-
formed to restore the blood flow. Another patient had
acute ischemia 5 days after the index procedure, which was
successfully treated with thrombolysis. An in-stent throm-
bosis occurred in one patient on day 12 after the index arocedure. Revascularization was achieved by placement of
femoropopliteal below the knee prosthetic bypass. One
atient complained of recidivating claudication on day 14
ue to an in-stent restenosis in the study stent, which was
uccessfully treated with thrombolysis, followed by percu-
aneous transluminal angioplasty with stent placement.
Compared with baseline, a significant improvement in
BI was found at the 1-month (0.97  0.09, P  .0001),
-month, (0.92  0.14, P  .0001), and 12-month
0.92  0.14, P  .0001) follow-up visits. The mean
utherford class decreased from 3.04 1.07 at baseline to
.68  1.13 at 1 year (P  .0001). During the 12-month
ollow-up period, stent occlusion occurred in 24 patients
nd stent restenosis in 10. Thirty of these patients received
repeat intervention.
Freedom from TLR after 12 months was 68.2% (Fig 1).
he 12-month primary patency rate for the total popula-
ion by Kaplan-Meier estimate was 64.8% (Fig 2). Stents
ith loss of patency were associated with a worsening in
utherford class and ABI. Fig 3 shows the primary patency
t 12 months in patients with a decrease in ABI of at least
.15. Stratification between lesions located in the superfi-
ial femoral artery only and those with popliteal artery
nvolvement showed a nonsignificant difference (P  .86)
or the 1-year primary patency rates of 65.6% for the former
nd 63.9% for the latter. Stratification between patients
ith and without diabetes mellitus showed 66.8% and
9.3% primary patency after 12 months, respectively, which
as not a statistically significant difference (P  .67). No
tatistically significant difference (P  .50) in 1-year pri-
ary patency rates was found in stratification between
ASC C (68.5%) and TASC D lesions (63.9%). Stratifica-
ions on the number of stents used did not show any
tatistical difference in 12-month primary patency rates,
hether one or multiple stents were implanted (Fig 4). The
atient survival rate for the entire population after 12
onths was 85.0% (Fig 5).
Stent fractures occurred in six patients (6.0%) when the
-ray images taken immediately after the procedure and
fter 1 year were compared. Mild stent fractures (fractures
f one strut) occurred in four patients (4.0%), and moder-
te fractures (fracture of one strut but without complete
eparation) were present in two (2.0%). No severe fractures
complete separation) were found. The occurrence of stent
ractures could not be linked to the number of stents
mplanted: two of the mild fractures occurred in patients
ith one stent implanted, and another two fractures oc-
urred in patients with two stents. Loss of primary patency
as reported in one patient with a moderate stent fracture.
he remaining five fractured stents were not associated
ith a loss of primary patency within the 1-year follow-up
eriod.
ISCUSSION
The main limitation of this prospective, multicenter,
ingle-arm, controlled study was the lack of a control
roup. Consequently, this study is not powered to report
ny relationships at a statistically significant level. Further-
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runoff and when the target lesion could be crossed.
Endovascular treatment of long femoropopliteal le-
sions and stent placement, in particular, remains a contro-
versial issue, and results in TASC C and D femoropopliteal
lesions are scarce. Percutaneous transluminal angioplasty in
Fig 1. Kaplan-Meier estimate shows freedom from targ
lation.
Fig 2. Kaplan-Meier estimate shows primarlonger SFA lesions has poor outcomes.10,11 The result with bubintimal angioplasty (SIA), a technique in which a dis-
ection is deliberately created, depends less on lesion length
ut depends rather on the presence of a healthy artery
roximal distal to the lesion. High technical success rates of
0% to 90% are reported, but SIA remains controversial
ecause primary patency rates at 12 months vary greatly
sion revascularization at 12 months for the total popu-
ency at 12 months for the total population.et leetween 22% and 79%.12-16 To date, the only results with
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Volume 54, Number 4 Bosiers et al 1047stent placement in SFA lesions 150 mm are those from a
subgroup analysis of the Zilver PTX registry, which con-
firms that stenting of long SFA lesions with the Zilver PTX
drug-eluting stent (DES; Cook, Bloomington, Ind) yields
Fig 3. Kaplan-Meier estimate shows primary patency a
decrease of at least 0.15.
Fig 4. Kaplan-Meier estimate after stratificacceptable 12-month results. At the Cardiovascular and anterventional Radiological Society of Europe (CIRSE)
ongress in 2009, Sapoval17 presented the results from a
ubgroup of 178 patients from the Zilver PTX Global
egistry with 182 TASC C and D lesions that were an
onths in patients with a standard ankle-brachial index
for implantation of one vs multiple stents.t 12 mverage length of 229 mm. He reported a freedom from
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October 20111048 Bosiers et altarget lesion revascularization rate of 79% after 12
months.17 Primary patency rates were presented by Bo-
siers18 at the 2010 CIRSE congress on a subgroup of 132
patients with 133 de novo lesions150 mm, which had an
average length of 226 mm. A 77.0% primary patency rate
was reported in this subgroup after 12 months.18
The Durability-200 reports a 12-month primary pa-
tency rate of 64.8%, which means there is a 20% difference
in results between endovascular stenting and surgical by-
pass. However, the success rates of surgical and endovascu-
lar procedures cannot be directly compared. Applying the
term patency to the surgical definition would mean that
vessel patency is maintained even in case of a high-grade
stenosis. Endovascular primary patency, however, refers to
an absence of binary restenosis.19 Because the endovascular
definition of primary patency is more strict, one could
expect the resulting rates to be lower.
A second observation is the 10% difference in results
between the Durability-200 results and those from the
Zilver PTX subgroup analysis. Yet, it is important to
notice that the price of a single DES is higher than that of
a long flexible SFA stent and that a higher number of
DES implantations are needed to treat TASC C and D
femoropopliteal lesions. In the Zilver PTX Global Reg-
istry subgroup of lesions 150 mm, an average of 3.7
stents were implanted vs 1.6 stents in comparable lesions
in our Durability-200 study. An elaborate discussion on
the economic aspects of DES for the treatment of de
novo lesions has been published.20
The stent fracture rate reported in the Durability-200
study was 6.0% after 12 months. Here also, the only data
currently available on stent fractures in TASC C and D
Fig 5. Kaplan-Meier estimate shows survfemoropopliteal lesions are those from the subgroup anal- ssis of the Zilver PTX Global Registry, which reported a
tent fracture rate of 2.6%.17 However, this rate is based on
he number of implanted stents instead of on the number of
esions, as is the case in Durability-200. Recalculating the
tent fracture rate from the Zilver PTX TASC C and D
roups on a lesion basis results in a fracture rate of 8.2%,
hich is more comparable to the Durability-200 fracture
ate of 6.0%.
Remarkably, there is a discrepancy between fracture
ates reported in Durability I and Durability-200, even
hough both studies were conducted with the Protégé
verFlex. Moreover, only one stent implantation was al-
owed in the Durability I study in contrast to Durability-
00, where multiple stent implantations were allowed. One
ould have expected a higher stent fracture rate in Durability-
00. However, the Durability I investigators identified the
mplantation technique as an influential factor of subse-
uent stent fracture. A 10% stent elongation occurred
uring implantation in 90% of all fractured stents within
his study.21 Elongated stent placement increases the
mount of continuous strain exerted on the stent struts,
esulting in more fractures. Because no elongated stent
lacement occurred in the Durability-200 study, the result-
ng lower fracture rate seems to confirm this thesis.
The Durability-200 study did not find any relationship
etween stent fractures and primary patency. Of the six
tent fractures found, five did not result in a loss of primary
atency. Also, the number of stents implanted did not
nfluence the occurrence of fractures. However, when frac-
ure severity is taken into consideration, we can see that
one of the mild fractures led to a loss of primary patency,
hereas one of the two moderate fractures was related. A
te at 12 months for the total population.imilar pattern was described by Durability I, where only
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Volume 54, Number 4 Bosiers et al 1049two of five severe fractures had no restenosis, hinting that
fracture severity may be an important factor to consider
when assessing the correlation between stent fractures and
loss of patency.
It is interesting to position the Durability-200 results
within the array of other current SFA studies. The FemPac,
Zilver PTX, RESILIENT (Randomized Study Comparing
the Edwards Self-Expanding LifeStent vs. Angioplasty-
alone in Lesions Involving the Superficial Femoral Artery or
Proximal Popliteal Artery), and THUNDER (Local Taxan
With Short Time and Exposure for Reduction of Restenosis
in Distal Arteries) studies have an average primary patency
rate of 80% (ranging between 76% and 83%) for lesions8
cm. The Durability I, Absolute (Abbott, Abbott Park, Ill),
and SUPERA stent studies (IDEV Technologies Inc, Web-
ster Tex) showed an average primary patency rate of 72%
(ranging, 63%-86%) for lesion lengths between 8 and 13
cm. The VIBRANT (VIABAHN Endoprosthesis Versus
Bare Nitinol Stent) study reported lesions with an average
length of 19 cm, treated with Viabahn implantation (W. L.
Gore and Associates, Flagstaff, Ariz) or stent placement.
The 12-month primary patency was 53% for the patients
treated with the Viabahn endoprosthesis and 58% for the
patients treated with a bare-metal stent. With these data in
mind, a primary patency 50% after 12 months of lesions
with an average length of 24 cm would follow the general
trend. This is schematically reported in Fig 6.
CONCLUSIONS
Our Durability-200 results show an acceptable primary
patency rate in this patient cohort with TASC C and D
femoropopliteal lesions after 1 year. Our findings definitely
warrant further investigation, preferably by means of ran-
domized trials. The release of more SFA stent data will
increase our understanding of the effect of stent design,
fracture occurrence, and its potential relationship with pa-
Fig 6. Positioning of the Durability-200 results compatency outcome.UTHOR CONTRIBUTIONS
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